A study to determine declining HCV incidence following rapid HCV treatment as prevention in Australian participants
Latest Information Update: 07 Apr 2022
Price :
$35 *
At a glance
- Drugs Sofosbuvir (Primary) ; Velpatasvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms SToP-C study
- 01 Apr 2022 Results assessing HCV reinfection risk following direct-acting antiviral therapy within Australian prisons that had opioid agonist therapy programs but not needle and syringe programs published in the Clinical Infectious Diseases
- 15 Oct 2020 New trial record
- 29 Aug 2020 Results presented at The International Liver Congress 2020